Loading patent…
AssigneeCellectis
InventorsRoman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
Estimating the term…
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
A T-cell comprising a first gene selectively inactivated by DNA cleavage by a first rare-cutting nuclease, wherein said first rare-cutting nuclease is a first TALE-nuclease directed against a PDCD1 (PD1) gene, wherein said first TALE-nuclease is directed against one of the gene target sequences of the PD-1 gene selected from the group consisting of SEQ ID NO:77 and SEQ ID NO:78, and wherein
Dependencies are inferred from the claim text.